OPQ’s FY2021 report gives mixed review on state of drug quality

Regulatory NewsRegulatory NewsAudit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaOTCPharmaceuticalsQuality Assurance and Control